Associated Papers
Potential Opportunities for Pharmacogenetic-Based Therapeutic Exploitation of Xanthine Dehydrogenase in Cardiovascular Disease.
Massimo G et al.
Antioxidants (basel, Switzerland), 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1
Somatic mutations reveal hyperactive Notch signaling and racial disparities in prurigo nodularis.
Rajeh A et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
37808834 (PubMed )
Supplement: media-2.xlsx › pnSomatic_supplement_tableS2
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
30206299 (PubMed )
Supplement: 41397_2018_44_MOESM5_ESM.xlsx › Sheet1
A case of xanthinuria type I with a novel mutation in xanthine dehydrogenase.
Iguchi A et al.
Cen Case Reports, 2016
Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
Park SK et al.
Scandinavian Journal of Gastroenterology, 2016
Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.
Ichida K et al.
International Journal of Molecular Sciences, 2012
Novel mutations in xanthine dehydrogenase/oxidase cause severe hypouricemia: biochemical and molecular genetic analysis in two Czech families with xanthinuria type I.
Stiburkova B et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Kinetics of 6-thioxanthine metabolism by allelic variants of xanthine oxidase.
Kudo M et al.
Drug Metabolism and Pharmacokinetics, 2010
Functional characterization of human xanthine oxidase allelic variants.
Kudo M et al.
Pharmacogenetics and Genomics, 2008
Select a paper to view details